Last reviewed · How we verify
NCT03506321: LANS
Comparison of the Benefit of Chromoendoscopy in Addition to High Definition White Light and Narrow Band Imaging for the Prediction of Submucosal Invasive Cancer in Colonic Lesions
NA trial testing chromoendoscopy, high definition white light and narrow band imaging in Colonic Adenoma in 400 participants. Completed in 7 February 2022.
7 March 2021
Quick facts
| Lead sponsor | Western Sydney Local Health District |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 400 |
| Start date | 7 February 2018 |
| Primary completion | 7 March 2021 |
| Estimated completion | 7 February 2022 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- chromoendoscopy, high definition white light and narrow band imaging
Conditions studied
- Colonic Adenoma — all drugs for Colonic Adenoma →
- Colon Polyp — all drugs for Colon Polyp →
- Submucosal Invasive Colon Adenocarcinoma — all drugs for Submucosal Invasive Colon Adenocarcinoma →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Western Sydney Local Health District — full company profile →
Who can join
18 and older, any sex, with Colonic Adenoma or Colon Polyp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the incremental benefit of chromoendoscopy in addition to high definition white light and narrow band imaging in predicting submucosal invasion within laterally spreading lesions in the colon and in determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Incremental benefit of dye-based chromoendoscopy to predict the risk of submucosal invasive cancer in large nonpedunculated colorectal polyps.
Sidhu M, Shahidi N, Vosko S, van Hattem WA, et al · · 2022 · cited 4× · PMID 34875258 · DOI 10.1016/j.gie.2021.11.032 -
UEG Week 2020 Oral Presentations.
· 2020 · cited 4× · PMID 33043828 · DOI 10.1177/2050640620927344
Verify or expand the search:
- PubMed search for NCT03506321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Western Sydney Local Health District trials
Trials by the same sponsor.
- NCT07445334 — Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes · NA · not yet recruiting
- NCT06360939 — Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease · NA · recruiting
- NCT06365411 — GEnomic Medicine in Kidney Transplantation Study · not yet recruiting
- NCT06828562 — GENomic Predictors in A Multi-Ethnic Population With Kidney Disease Study · enrolling by invitation
- NCT05509153 — A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03506321 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western Sydney Local Health District
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03506321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing